HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Robert S Rosenson Selected Research

Niacin (Nicotinic Acid)

10/2015Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease: A Retrospective Cohort Study in the Medicare Population 2007 to 2011.
9/2004Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes.
11/2003Antiatherothrombotic effects of nicotinic acid.
7/2002Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Robert S Rosenson Research Topics

Disease

91Cardiovascular Diseases (Cardiovascular Disease)
04/2024 - 07/2002
47Coronary Disease (Coronary Heart Disease)
01/2022 - 01/2002
32Atherosclerosis
01/2024 - 01/2002
30Myocardial Infarction
04/2023 - 07/2002
29Dyslipidemias (Dyslipidemia)
03/2024 - 07/2002
24Type 2 Diabetes Mellitus (MODY)
03/2024 - 07/2002
20Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2014 - 11/2003
19Hypercholesterolemia
03/2024 - 11/2003
15Inflammation (Inflammations)
03/2024 - 07/2003
15Stroke (Strokes)
01/2023 - 09/2007
13COVID-19
03/2024 - 10/2020
13Acute Coronary Syndrome
10/2018 - 12/2002
11Coronary Artery Disease (Coronary Atherosclerosis)
02/2023 - 07/2002
10Hyperlipidemias (Hyperlipidemia)
03/2024 - 02/2008
10Hypertriglyceridemia
11/2023 - 04/2002
8Chronic Renal Insufficiency
07/2023 - 01/2019
8Insulin Resistance
09/2011 - 06/2004
7Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
01/2024 - 01/2017
7Heart Failure
11/2023 - 07/2003
7Ischemic Stroke
07/2023 - 05/2008
7Muscular Diseases (Myopathy)
01/2018 - 03/2004
6Diabetes Mellitus
02/2022 - 04/2002
5Peripheral Arterial Disease
11/2022 - 01/2017
5Rhabdomyolysis
02/2022 - 03/2014
5Skeletal Abnormalities Mandibular Hypoplasia Auditory Canal Atresia Short Stature
01/2018 - 02/2016
5Vascular Diseases (Vascular Disease)
01/2018 - 07/2005
5Myalgia
01/2018 - 03/2014
4Pancreatitis
04/2024 - 07/2021
4Homozygous Familial Hypercholesterolemia
03/2024 - 01/2020
4Hypertension (High Blood Pressure)
09/2022 - 07/2003
4Critical Illness (Critically Ill)
08/2021 - 04/2006
3Thrombosis (Thrombus)
03/2024 - 11/2003
3Body Weight (Weight, Body)
12/2020 - 08/2002
3Sepsis (Septicemia)
01/2019 - 04/2006
3Unstable Angina
09/2010 - 07/2002
3Obesity
11/2008 - 07/2003
2Weight Loss (Weight Reduction)
03/2024 - 09/2004
2Hyperlipoproteinemia Type I (Lipoprotein Lipase Deficiency, Familial)
11/2023 - 01/2023
2Aortic Valve Stenosis (Aortic Stenosis)
06/2023 - 01/2023
2Cerebrovascular Disorders (Cerebrovascular Occlusion)
11/2022 - 01/2020

Drug/Important Bio-Agent (IBA)

94Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
03/2024 - 01/2002
59oxidized low density lipoproteinIBA
03/2024 - 12/2002
52LDL CholesterolIBA
03/2024 - 11/2003
50LipidsIBA
11/2023 - 11/2002
33Lipoproteins (Lipoprotein)IBA
03/2024 - 01/2002
32Triglycerides (Triacylglycerol)IBA
04/2024 - 04/2002
29HDL CholesterolIBA
01/2023 - 07/2002
21Ezetimibe (Zetia)FDA Link
04/2024 - 03/2014
19Proprotein Convertase 9IBA
04/2024 - 06/2016
18CholesterolIBA
04/2023 - 04/2005
16Biomarkers (Surrogate Marker)IBA
01/2019 - 08/2005
15LDL Lipoproteins (beta Lipoproteins)IBA
11/2023 - 07/2002
13evolocumabIBA
03/2024 - 03/2014
12Atorvastatin (Lipitor)FDA Link
10/2022 - 10/2007
11Glucose (Dextrose)FDA LinkGeneric
11/2023 - 09/2004
10ApolipoproteinsIBA
01/2023 - 02/2008
10Secretory Phospholipases A2IBA
01/2014 - 02/2009
9Fenofibrate (CiL)FDA LinkGeneric
10/2022 - 08/2007
9Rosuvastatin Calcium (Crestor)FDA Link
09/2022 - 11/2003
9HDL LipoproteinsIBA
10/2021 - 05/2005
91-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA
01/2018 - 02/2008
8Phospholipases (Phospholipase)IBA
03/2014 - 02/2009
8varespladib methylIBA
12/2012 - 02/2009
7evinacumabIBA
03/2024 - 01/2020
7Fibric Acids (Fibrates)IBA
10/2015 - 09/2004
6C-Reactive ProteinIBA
07/2023 - 07/2002
6Lipoprotein(a)IBA
07/2023 - 01/2021
6EnzymesIBA
02/2022 - 07/2003
5PCSK9 InhibitorsIBA
01/2023 - 01/2018
5CytokinesIBA
01/2023 - 02/2005
5Angiotensin Receptor AntagonistsIBA
01/2023 - 07/2003
5Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
01/2023 - 11/2002
5Insulin (Novolin)FDA Link
10/2020 - 09/2004
5Colesevelam Hydrochloride (Welchol)FDA Link
06/2014 - 04/2006
5fenofibric acidFDA Link
06/2014 - 12/2010
4Monoclonal AntibodiesIBA
04/2024 - 06/2016
4Niacin (Nicotinic Acid)FDA LinkGeneric
10/2015 - 07/2002
4IsoenzymesIBA
04/2011 - 11/2009
3Lipoprotein Lipase (Diacylglycerol Lipase)IBA
11/2023 - 02/2008
3alirocumabIBA
02/2022 - 02/2017
3Heparin (Liquaemin)FDA LinkGeneric
08/2021 - 10/2020
3Hypolipidemic Agents (Antihyperlipidemics)IBA
12/2018 - 10/2016
3Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
10/2018 - 11/2002
3Metformin (Glucophage)FDA LinkGeneric
06/2014 - 09/2004
3varespladibIBA
01/2014 - 11/2009
3darapladibIBA
06/2013 - 09/2012
3Oxidoreductases (Dehydrogenase)IBA
02/2011 - 01/2002
3Fatty Acids (Saturated Fatty Acids)IBA
08/2009 - 08/2007
3Fibrinogen (Factor I)FDA Link
07/2003 - 04/2002
3Pravastatin (Pravachol)FDA LinkGeneric
12/2002 - 01/2002
2Interleukin-6 (Interleukin 6)IBA
03/2024 - 01/2023
2NexusIBA
03/2024 - 01/2023
2Angiopoietin-Like Protein 3IBA
11/2023 - 01/2021
2Amyloid (Amyloid Fibrils)IBA
06/2023 - 01/2023
2AngiopoietinsIBA
01/2023 - 01/2020
2SodiumIBA
01/2023 - 01/2022
2LDL Receptors (LDL Receptor)IBA
01/2023 - 01/2021

Therapy/Procedure

98Therapeutics
03/2024 - 07/2002
5Drug Therapy (Chemotherapy)
11/2023 - 05/2005
5Secondary Prevention
02/2023 - 11/2002